In a retrospective cohort of 185 patients with multiple sclerosis treated with ocrelizumab, 176 infections were reported, in 46.1% of patients. |
Odds of infection in univariate and multivariable analyses were not uniform, with increasing IgA and IgG and multiple clinical factors being associated with reduced odds of infection. |